SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D - General statement of acquisition of beneficial ownership:
SEC Accession No. 0001144204-16-141978
Filing Date
2017-01-03
Accepted
2016-12-30 18:06:10
Documents
6

Document Format Files

Seq Description Document Type Size
1 SCHEDULE 13D v456014_sc13d.htm SC 13D 61889
2 EXHIBIT 99.1 v456014_ex99-1.htm EX-99.1 743133
3 EXHIBIT 99.2 v456014_ex99-2.htm EX-99.2 73499
4 EXHIBIT 99.3 v456014_ex99-3.htm EX-99.3 74029
5 EXHIBIT 99.4 v456014_ex99-4.htm EX-99.4 80859
6 EXHIBIT 99.5 v456014_ex99-5.htm EX-99.5 74819
  Complete submission text file 0001144204-16-141978.txt   1109988
Mailing Address 8285 EL RIO STREET SUITE 130 HOUSTON TX 77054
Business Address 8285 EL RIO STREET SUITE 130 HOUSTON TX 77054 713-842-1249
PLX PHARMA INC. (Filed by) CIK: 0001291520 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D
SIC: 2834 Pharmaceutical Preparations

Mailing Address 14 WALL ST. SUITE 3D NEW YORK NY 10005
Business Address 14 WALL ST. SUITE 3D NEW YORK NY 10005 212-269-2834
Dipexium Pharmaceuticals, Inc. (Subject) CIK: 0001497504 (see all company filings)

IRS No.: 271707962 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-88072 | Film No.: 162078210
SIC: 2834 Pharmaceutical Preparations